Pfizer applies for EUA for variant-tailored booster; unveils new efficacy data for youngest children
Pfizer yesterday announced its application for an emergency use authorization for a COVID-19 vaccine booster that is designed to protect against the SARS-CoV-2 omicron variant. The booster is meant for the 12 and older age group. Pfizer’s application includes clinical data for bivalent Omicron BA.1-adapted vaccine and pre-clinical and manufacturing data from the companies’ bivalent Omicron BA.4/BA.5-adapted vaccine.
Pfizer today also released updated data on the efficacy of its COVID-19 vaccine when used for children between the ages of six months and four years old, indicating a 70% effectiveness across existing SARS-CoV-2 variants.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…